1 week Ago By ABMN Staff
National Bank of Canada FI reduced its holdings in Elevance Health, Inc. ( NYSE:ELV – Free Report ) by 0.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 27,821 shares of the company’s stock after selling 257 shares during the period. National Bank of Canada FI’s holdings in Elevance Health were worth $14,837,000 as of its most recent SEC filing. Several other institutional investors also recently added to or reduced their stakes in ELV.
Norges Bank bought a new position in Elevance Health in the 4th quarter worth approximately $1,347,434,000. Massachusetts Financial Services Co. MA bought a new position in Elevance Health in the 4th quarter worth approximately $467,141,000.
Morningstar Investment Services LLC bought a new position in Elevance Health in the 4th quarter worth approximately $239,244,000. Focused Investors Fund L P bought a new position in Elevance Health in the 1st quarter worth approximately $249,884,000. Finally, M&G Plc bought a new stake in shares of Elevance Health during the first quarter valued at approximately $203,389,000.
89.24% of the stock is owned by institutional investors. Elevance Health Price Performance Elevance Health stock opened at $541.
91 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.
49 and a current ratio of 1.49. The firm has a market cap of $125.
95 billion, a P/E ratio of 20.48, a P/E/G ratio of 1.22 and a beta of 0.
84. The business’s fifty day moving average is $533.79 and its two-hundred day moving average is $526.
61. Elevance Health, Inc. has a 52 week low of $431.
38 and a 52 week high of $567.26. Elevance Health Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th.
Stockholders of record on Tuesday, September 10th will be paid a dividend of $1.63 per share. This represents a $6.
52 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Tuesday, September 10th.
Elevance Health’s dividend payout ratio (DPR) is presently 24.64%. Insider Activity In other news, Director Robert L.
Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.
76, for a total transaction of $154,561.80. Following the transaction, the director now owns 9,721 shares of the company’s stock, valued at $4,926,213.
96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink . In other news, Director Robert L.
Dixon, Jr. sold 305 shares of the company’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $506.
76, for a total transaction of $154,561.80. Following the transaction, the director now owns 9,721 shares of the company’s stock, valued at $4,926,213.
96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, CEO Gail Boudreaux sold 34,000 shares of the company’s stock in a transaction on Monday, July 22nd.
The shares were sold at an average price of $500.98, for a total value of $17,033,320.00.
Following the transaction, the chief executive officer now directly owns 126,709 shares in the company, valued at approximately $63,478,674.82. The disclosure for this sale can be found here .
Insiders have sold 35,058 shares of company stock valued at $17,588,116 over the last 90 days. 0.35% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades A number of analysts have recently issued reports on the company. Stephens restated an “overweight” rating and set a $615.00 price objective on shares of Elevance Health in a research report on Thursday.
Wells Fargo & Company lowered their price objective on Elevance Health from $600.00 to $593.00 and set an “overweight” rating on the stock in a research report on Monday, July 22nd.
Royal Bank of Canada boosted their price objective on Elevance Health from $575.00 to $585.00 and gave the company an “outperform” rating in a research report on Thursday, July 18th.
Robert W. Baird assumed coverage on Elevance Health in a research report on Thursday, May 30th. They set an “outperform” rating and a $649.
00 price objective on the stock. Finally, TD Cowen lowered their price objective on Elevance Health from $624.00 to $589.
00 and set a “buy” rating on the stock in a research report on Friday, July 19th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.
com, the stock presently has an average rating of “Buy” and a consensus target price of $604.29. Check Out Our Latest Report on Elevance Health Elevance Health Profile ( Free Report ) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States.
The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Read More Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Elevance Health, Inc. ( NYSE:ELV – Free Report ). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.
com's FREE daily email newsletter ..
